Emerging cell and gene therapy innovations signal progress in treating diverse diseases. CRISPR-edited 'hypoimmune' pancreatic islet cells can now be transplanted without immunosuppression for type 1 diabetes, addressing prior treatment limitations. Efforts toward universal CAR T therapies targeting CD70 show promise for renal cell carcinoma, aiming at off-the-shelf solutions. The NIH launched an $87 million Standardized Organoid Modeling Center to accelerate replacement of animal models, conveying commitment to ethical and rapid therapy development.